Novartis reported two Phase 3 wins for remibrutinib (Rhapsido) in multiple sclerosis, describing “superiority” versus Aubagio on annualized relapse rates and inflammatory brain lesion measures across identical studies. The company also said disability progression signals were “clinically meaningful,” while liver safety outcomes did not show the safety issues that have complicated other BTK inhibitors in MS. The company did not provide detailed results in the update, but investors reacted positively to the topline positioning for remibrutinib as it aims to counter revenue pressure from multiple patent expirations. Novartis said it plans to share study results with regulators. Analyst commentary in the reporting highlighted the scale of potential peak sales if MS adoption materializes, while also pointing to the central role of liver safety details for regulator and payer confidence. For biotech peers, the data underscore a key late-stage differentiation theme in neuroimmunology: CNS exposure plus a tolerability profile clean enough to enable broader long-term use.